OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Phase 2
Recruiting
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: EB-1020 (Centanafadine) 164.4 mgDrug: EB-1020 (Centanafadine) 328.8 mgDrug: Placebo
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 630
- Registration Number
- NCT06931080
- Locations
- 🇯🇵
Maynds Tower Mental Clinic, Tokyo, Japan
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Phase 3
Recruiting
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: EB-1020 (Centanafadine) 164.4 mgDrug: EB-1020 (Centanafadine) 328.8 mg
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06926829
- Locations
- 🇯🇵
Maynds Tower Mental Clinic, Tokyo, Japan
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Recruiting
- Conditions
- Alzheimer Disease
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06875986
- Locations
- 🇯🇵
Pharmacovigilance Department, Osaka, Japan
Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 59
- Registration Number
- NCT06036108
- Locations
- 🇯🇵
Rainbow & Sea Hospital, Saga-shi, Japan
Samtasu Post-marketing General Drug Use-results Survey in Patients with Volume Overload in Heart Failure.
Recruiting
- Conditions
- Heart Failure
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1600
- Registration Number
- NCT05712746
- Locations
- 🇯🇵
Pharmacovigilance Department, Osaka, Japan
A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Phase 3
Completed
- Conditions
- Hyper-low-density Lipoprotein (LDL) Cholesterolemia
- Interventions
- Drug: 180mg of ETC-1002(bempedoic acid)
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT05687071
- Locations
- 🇯🇵
Rinku General Medical Center, Izumisano-shi, Japan
A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Phase 3
Completed
- Conditions
- Hyper-low-density Lipoprotein (LDL) Cholesterolemia
- Interventions
- Drug: PlaceboDrug: 180mg of ETC-1002(bempedoic acid)
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT05683340
- Locations
- 🇯🇵
Rinku General Medical Center, Izumisano-shi, Japan
A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Phase 2
Completed
- Conditions
- Cardiac Edema (CHF)
- Interventions
- Drug: OPC 131461 2mg groupDrug: OPC 131461 5mg groupDrug: PlaceboDrug: OPC 131461 10mg groupDrug: OPC 131461 1mg group
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 157
- Registration Number
- NCT05615363
- Locations
- 🇯🇵
Harasanshin Hospital, Fukuoka, Japan
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT05372653
- Locations
- 🇯🇵
Sotobo Children's Clinic, Isumi, Japan
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Recruiting
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT05342493
- Locations
- 🇯🇵
Pharmacovigilance Department, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath